JP2022510962A5 - - Google Patents
Info
- Publication number
- JP2022510962A5 JP2022510962A5 JP2021531115A JP2021531115A JP2022510962A5 JP 2022510962 A5 JP2022510962 A5 JP 2022510962A5 JP 2021531115 A JP2021531115 A JP 2021531115A JP 2021531115 A JP2021531115 A JP 2021531115A JP 2022510962 A5 JP2022510962 A5 JP 2022510962A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- crenolanib
- pharmaceutical composition
- composition according
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779128P | 2018-12-13 | 2018-12-13 | |
| US62/779,128 | 2018-12-13 | ||
| US201962861424P | 2019-06-14 | 2019-06-14 | |
| US62/861,424 | 2019-06-14 | ||
| US16/713,935 | 2019-12-13 | ||
| US16/713,935 US11602533B2 (en) | 2018-12-13 | 2019-12-13 | Crenolanib combination therapy |
| PCT/US2019/066308 WO2020123991A1 (en) | 2018-12-13 | 2019-12-13 | Crenolanib combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510962A JP2022510962A (ja) | 2022-01-28 |
| JP2022510962A5 true JP2022510962A5 (cg-RX-API-DMAC7.html) | 2022-12-20 |
Family
ID=69596002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531115A Pending JP2022510962A (ja) | 2018-12-13 | 2019-12-13 | クレノラニブ併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11602533B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3893874A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022510962A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110840893A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020123991A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110840893A (zh) * | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
| CN113491693B (zh) * | 2020-03-19 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 法米替尼或其可药用盐在制备治疗Ras突变疾病的药物中的用途 |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US20220047574A1 (en) * | 2020-08-15 | 2022-02-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pdgfr alpha mutated proliferative disorders |
| US20220079934A1 (en) * | 2020-09-17 | 2022-03-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pain |
| CN118576599A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药(上海)有限公司 | 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| DK1641780T3 (da) | 2003-06-24 | 2009-02-02 | Pfizer Prod Inc | Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater |
| US20130230511A1 (en) | 2012-02-03 | 2013-09-05 | Board Of Regents, The University Of Texas System | Biomarkers for response to tyrosine kinase pathway inhibitors in cancer |
| JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. | 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法 |
| CN105007939B (zh) * | 2012-10-05 | 2018-10-19 | 卡德门企业有限公司 | 人抗vegfr-2/kdr抗体 |
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| US9617521B2 (en) * | 2013-10-21 | 2017-04-11 | Hemoshear, Llc | In vitro model for a tumor microenvironment |
| EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| EP3120851A1 (en) * | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| CN110840893A (zh) * | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
-
2019
- 2019-09-26 CN CN201910917756.5A patent/CN110840893A/zh active Pending
- 2019-12-13 JP JP2021531115A patent/JP2022510962A/ja active Pending
- 2019-12-13 WO PCT/US2019/066308 patent/WO2020123991A1/en not_active Ceased
- 2019-12-13 US US16/713,935 patent/US11602533B2/en active Active
- 2019-12-13 EP EP19896570.9A patent/EP3893874A4/en not_active Withdrawn
-
2023
- 2023-02-09 US US18/166,636 patent/US20230181565A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108601831B (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| Ellis et al. | Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non–small cell lung cancer patients | |
| US20230181565A1 (en) | Crenolanib combination therapy | |
| JP2011511071A (ja) | 肺癌を治療するためのピコプラチンおよびアムルビシン | |
| CN104436194B (zh) | 具有协同增效作用的抗癌组合物 | |
| CN114173785B (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| WO2010086964A1 (ja) | がん治療のための併用療法 | |
| JP2008514577A5 (cg-RX-API-DMAC7.html) | ||
| JP2019536783A5 (cg-RX-API-DMAC7.html) | ||
| CN112236147A (zh) | 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法 | |
| JP2019038797A5 (cg-RX-API-DMAC7.html) | ||
| Kamura et al. | Chemotherapy for advanced or recurrent cervical cancer | |
| JP2023517671A5 (cg-RX-API-DMAC7.html) | ||
| KR20230036274A (ko) | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 | |
| Horn et al. | Emerging data with antiangiogenic therapies in early and advanced non–small-cell lung cancer | |
| TW201628608A (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| JP2016539149A5 (cg-RX-API-DMAC7.html) | ||
| Mizushima et al. | A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer | |
| CN116672345A (zh) | Parp抑制剂和细胞毒性剂的联合产品及其用途 | |
| KR102265488B1 (ko) | 암 화학 요법시의 부작용 경감제 | |
| CN119278047A (zh) | 用于预防或治疗癌症的adp-核糖结合肽及adp-核糖的联合疗法 | |
| HK40017631A (en) | Pharmaceutical compositions containing crenolanib and use thereof | |
| Gore et al. | Chemotherapy and Colorectal Cancer | |
| CA3255803A1 (en) | Combination therapy with adp-ribose binding peptide and adp-ribose for prevention or treatment of cancer |